Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834463 | 0.83 | PGR (0.59) | ATMPDK2PDK4EPHX2PIK3CD | |
| SCHEMBL2787601 | 0.81 | PIK3CD (0.48) | EPHX2PIK3CDPGRPIK3R1LMNA | |
| SCHEMBL3023025 | 0.77 | EPHX2 (0.53) | EPHX2PIK3CDPGRPIK3R1 | |
| SCHEMBL3020687 | 0.77 | PGR (0.76) | EPHX2PIK3CDPGRPIK3R1 | |
| SCHEMBL3019951 | 0.76 | PGR (0.58) | EPHX2PIK3CDPGRPIK3R1 | |
| SCHEMBL8066741 | 0.76 | PGR (0.53) | EPHX2PIK3CDPGRPIK3R1 | |
| SCHEMBL19216467 | 0.74 | PLK4 (0.52) | ATMPDK2PDK4EPHX2PIK3CD | |
| SCHEMBL24740182 | 0.74 | PDK2 (0.60) | ATMPDK2PDK4POLBSMN1; SMN2 | |
| SCHEMBL5500770 | 0.74 | PDK2 (0.60) | ATMPDK2PDK4POLBSMN1; SMN2 | |
| SCHEMBL8052840 | 0.73 | PGR (0.55) | EPHX2PIK3CDPGRPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273749-B2 | N-substituted oxindoline derivatives as calcium channel blockers | MERCK SHARP & DOHME CORP. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2209373-B1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2209373-B1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK SHARP & DOHME (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO. INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | DUFFY JOSEPH L | 2010-08-12 | — | — | US | disclosed |
| EP-2209373-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2205079-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009045386-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045386-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045381-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045381-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204247-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | ATM 3952/4885PDK2 2738/4885PDK4 2639/4885 |
| US-20100216815-A1 | N-SUBSTITUTED OXINDOLINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1D, TRPV1 | ATM 3952/4885PDK2 2738/4885PDK4 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.